Potential Cure for Epilepsy: Cannabis Vastly Reduces Seizures in Boy with Dravet Syndrome

A judge checks on a marijuana sample during a judging session at Uruguay's second

“Scientists are looking at the potential use of cannabis to treat and potentially cure severe forms of epilepsy.

The medical benefits of medical marijuana for neurological conditions like epilepsy are highly debated.

Examining the potential use of the drug, a series of articles in the journal Epilepsia, a journal of the International League Against Epilepsy, looks at its potential use for treating the syndrome.

Edward Maa, from the Comprehensive Epilepsy Program at Denver Health in Denver, Colorado, looks at a case study of a child with Dravet syndrome – a very severe form of epilepsy.

In the case, a mother provided her child with a strain of medical marijuana high in Cannabidiol (CBD) and tetrahydrocannabinol (THC) known as Charlotte’s Web.

When used with the child’s normal drug regime, seizures dropped from 50 convulsions per day to just two or three per month.”

http://www.ibtimes.co.uk/potential-cure-epilepsy-cannabis-vastly-reduces-seizures-boy-dravet-syndrome-1449505

http://www.thctotalhealthcare.com/category/dravet-syndome/

 

Toddler’s seizures stopped after consuming cannabis oil, parents say

Two-year-old Kyla Williams hasn‘t learned to walk or talk, her development has stopped as she suffered as many as 200 seizures daily and no medication helped. Now the girl’s family say she hasn’t had a seizure in a week, ever since they began giving her cannabis oil extracted from hemp. (handout from family)

“Two-year-old Kyla Williams hasn’t learned to walk or talk, her development has stopped as she suffered as many as 200 seizures daily and no medication helped. Now the girl’s family says she hasn’t had a seizure in a week, ever since they began giving her cannabis oil extracted from hemp.

The oil being used by the toddler has high amounts of cannabidiol, known as CBD, the main ingredient in medical marijuana, and almost no psychoactive ingredients.”

http://www.theglobeandmail.com/news/british-columbia/toddlers-seizures-stopped-after-consuming-cannabis-oil-parents-say/article18769814/

http://www.thctotalhealthcare.com/category/epilepsy-2/

 

Marijuana Effectively Reduces Seizures in Epilepsy Patients

marijuanas

“Medicinal uses of marijuana have been a matter for heated debate for quite some time now. A review by American Academy of neurology collated all available information on marijuana use for brain disease treatment and concluded that except for treating symptoms of multiple sclerosis, there is no hard evidence in favor of medical usage of marijuana.

But now some articles have been published in the journal Epilepsia that contradicts the earlier review. One of these articles is a case study of a family living in Denver, CO. The child in the family suffers from a severe form of epilepsy known as Dravet Syndrome and used to have frequent seizures, as many as 50 convulsions a day. But the child was given “Charlotte’s Web”- a marijuana strain with high levels of cannabidiol (CBD) and tetrahydrocannabinol (THC). Reportedly, the seizures decreased considerably and now the child suffers from only 2 or 3 seizures each month.

According to the author of the article, Dr. Edward Maa, “As medical professionals it is important that we further the evidence of whether CBD in cannabis is an effective antiepileptic therapy.””

http://www.newsonwellness.com/2014/05/marijuana-effectively-reduces-seizures-epilepsy-patients/

http://www.thctotalhealthcare.com/category/epilepsy-2/

Study examines potential use of medical marijuana, CBD in treating epilepsy

“…cannabis has been used to treat epilepsy for centuries… The therapeutic potential of medical marijuana and pure cannabidiol (CBD), an active substance in the cannabis plant, for neurologic conditions is highly debated. A series of articles published in Epilepsia, a journal of the International League Against Epilepsy (ILAE), examine the potential use of medical marijuana and CBD in treating severe forms of epilepsy…”

http://www.news-medical.net/news/20140523/Study-examines-potential-use-of-medical-marijuana-CBD-in-treating-epilepsy.aspx

http://www.thctotalhealthcare.com/category/epilepsy-2/

Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series.

“Cannabidiol (CBD) is the main non-psychotropic component of the Cannabis sativa plant. REM sleep behaviour disorder (RBD) is a parasomnia characterized by the loss of muscle atonia during REM sleep associated with nightmares and active behaviour during dreaming. We have described the effects of CBD in RBD symptoms in patients with Parkinson’s disease.

CASES SUMMARY:

Four patients treated with CBD had prompt and substantial reduction in the frequency of RBD-related events without side effects.

WHAT IS NEW AND CONCLUSION:

This case series indicates that CBD is able to control the symptoms of RBD.”

http://www.ncbi.nlm.nih.gov/pubmed/24845114

Potential effects of cannabidiol as a wake-promoting agent.

“Over the last decades, the scientific interest in chemistry and pharmacology of cannabinoids has increased. Most attention has focused on ∆(9)-tetrahydrocannabinol (∆(9)-THC) as it is the psychoactive constituent of Cannabis sativa (C. sativa). However, in previous years, the focus of interest in the second plant constituent with non-psychotropic properties, cannabidiol (CBD) has been enhanced. Recently, several groups have investigated the pharmacological properties of CBD with significant findings; furthermore, this compound has raised promising pharmacological properties as a wake-inducing drug. In the current review, we will provide experimental evidence regarding the potential role of CBD as a wake-inducing drug.”

http://www.ncbi.nlm.nih.gov/pubmed/24851090

Cannabinoid-induced autophagy regulates suppressor of cytokine signaling (SOCS)-3 in intestinal epithelium.

“Autophagy is a catabolic process involved in homeostatic and regulated cellular protein recycling and degradation via the lysosomal degradation pathway. Emerging data associates impaired autophagy, increased activity in the endocannabinoid system and upregulation of suppressor of cytokine signaling (SOCS)-3 protein expression during intestinal inflammatory states. We have investigated whether these three processes are linked. By assessing the impact of phyto-cannabinoid cannabidiol (CBD), synthetic cannabinoid (ACEA) and endocannabinoid (AEA) on autophagosome formation, we explored whether these actions were responsible for cyclic SOCS3 protein levels. Our findings show that all three cannabinoids induce autophagy in a dose-dependent manner in fully differentiated CaCo2 cells, a model of mature intestinal epithelium. ACEA and AEA induced canonical autophagy, which was cannabinoid receptor (CB)-1 mediated. In contrast, CBD was able to bypass both the CB1 receptor and the canonical pathway to induce autophagy, albeit to a lesser extent. Functionally, all three cannabinoids reduced SOCS3 protein expression, which was reversed by blocking both early and late autophagy. In conclusion, the regulatory protein, SOCS3, is itself regulated by autophagy and cannabinoids play a role in this process, which could be important when considering therapeutic applications for the cannabinoids in inflammatory conditions.”

http://www.ncbi.nlm.nih.gov/pubmed/24833710

Intrahypothalamic injection of cannabidiol increases the extracellular levels of adenosine in nucleus accumbens in rats.

“Cannabidiol (CBD) is a constituent of Cannabis sativa that promotes wakefulness as well as enhances endogenous levels of wake-related neurotransmitters, including dopamine. However, at this date, the effects of CBD on the sleep-inducing molecules, such as adenosine (AD), are unknown. Here, we report that intrahypothalamic injection of CBD (10μg/1μL) increases the extracellular levels of AD collected from nucleus accumbens. Furthermore, the pharmacodynamic of this drug shows that effects on the contents of AD last 2h post-injection. These preliminary findings suggest that CBD promotes the endogenous accumulation of AD.”

http://www.ncbi.nlm.nih.gov/pubmed/24800644

“Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats…Since CBD induces alertness, it might be of therapeutic value in sleep disorders such as excessive somnolence.”  http://www.ncbi.nlm.nih.gov/pubmed/16844117

“The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent.”  http://www.ncbi.nlm.nih.gov/pubmed/19045957

http://www.thctotalhealthcare.com/category/insomnia/

Therapeutic Satisfaction and Subjective Effects of Different Strains of Pharmaceutical-Grade Cannabis.

“The aims of this study are to assess the therapeutic satisfaction within a group of patients using prescribed pharmaceutical-grade cannabis and to compare the subjective effects among the available strains with special focus on their delta-9-tetrahydrocannabinol and cannabidiol content…

One hundred two patients were included; their average age was 53 years and 76% used it for more than a year preceding this study. Chronic pain (53%; n = 54) was the most common medical indication for using cannabis followed by multiple sclerosis (23%; n = 23), and 86% (n = 88) of patients (almost) always experienced therapeutic satisfaction when using pharmaceutical cannabis.

These results show that patients report therapeutic satisfaction with pharmaceutical cannabis, mainly pain alleviation. Some subjective effects were found to differ among the available strains of cannabis, which is discussed in relation to their different tetrahydrocannabinol/cannabidiol content. These results may aid in further research and critical appraisal for medicinally prescribed cannabis products.”

http://www.ncbi.nlm.nih.gov/pubmed/24747979

Marijuana Compound May Help Stop Diabetic Retinopathy

“A compound found in marijuana won’t make you high but it may help keep your eyes healthy if you’re a diabetic, researchers say. Early studies indicate cannabidiol works as a consummate multi-tasker to protect the eye from growing a plethora of leaky blood vessels, the hallmark of diabetic retinopathy, says Dr. Gregory I. Liou, molecular biologist at the Medical College of Georgia.”

http://www.sciencedaily.com/releases/2006/02/060227184647.htm